MSD unveils bid to tackle coronavirus pandemic
The group will work on two experimental vaccines and an antiviral
Read More
Tag: THEMIS
Brilinta reduces CV events but increases bleeding
The drug reduced the relative risk for the composite of cardiovascular death, heart attack, or stroke by 10% compared with aspirin alone.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
